Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBTNASDAQ:DARENASDAQ:MIRANASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.73-2.3%$3.44$2.11▼$12.60$5.16M-0.03482,301 shs20,538 shsDAREDare Bioscience$2.40$2.88$2.35▼$4.60$21.24M1.1435,113 shs10,232 shsMIRAMIRA Pharmaceuticals$1.18-5.2%$1.25$0.51▼$5.01$19.88M1.722.34 million shs18.91 million shsPASGPassage Bio$0.46+13.5%$0.37$0.26▼$1.33$28.65M1.67375,068 shs499,654 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare-2.33%-21.24%-22.14%-30.13%-64.38%DAREDare Bioscience0.00%-8.75%-22.33%-16.96%-22.33%MIRAMIRA Pharmaceuticals-5.24%-2.89%-14.86%+40.82%+104.35%PASGPassage Bio+13.46%+39.70%-7.62%+35.59%-48.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare2.2917 of 5 stars0.05.00.04.32.61.70.0DAREDare Bioscience1.767 of 5 stars3.35.00.00.00.60.00.0MIRAMIRA Pharmaceuticals3.0042 of 5 stars3.75.00.00.02.10.00.6PASGPassage Bio2.8931 of 5 stars3.53.00.00.01.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ADAREDare Bioscience 2.50Moderate Buy$12.00400.00% UpsideMIRAMIRA Pharmaceuticals 3.33Buy$14.001,091.49% UpsidePASGPassage Bio 3.00Buy$7.501,526.90% UpsideCurrent Analyst Ratings BreakdownLatest ALBT, MIRA, DARE, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.37M3.77N/AN/A($11.37) per share-0.24DAREDare Bioscience$10K2,124.00N/AN/A($0.69) per share-3.48MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/APASGPassage BioN/AN/AN/AN/A$0.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-647.29%N/A-50.13%8/18/2025 (Estimated)DAREDare Bioscience-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)PASGPassage Bio-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)Latest ALBT, MIRA, DARE, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A5/13/2025Q1 2025DAREDare Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.190.19DAREDare BioscienceN/A0.560.56MIRAMIRA PharmaceuticalsN/A12.8612.86PASGPassage BioN/A3.743.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%DAREDare Bioscience6.70%MIRAMIRA Pharmaceuticals35.16%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%DAREDare Bioscience4.00%MIRAMIRA Pharmaceuticals6.65%PASGPassage Bio5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million1.19 millionNot OptionableDAREDare Bioscience308.85 million8.50 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.80 millionNot OptionablePASGPassage Bio13062.15 million59.04 millionOptionableALBT, MIRA, DARE, and PASG HeadlinesRecent News About These CompaniesPassage Bio, Inc. (PASG) Income Statement - Yahoo FinanceJuly 1 at 7:02 AM | finance.yahoo.comPASG Passage Bio, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 SharesJune 27, 2025 | insidertrades.comChardan Capital Reiterates Buy Rating for Passage Bio (NASDAQ:PASG)June 26, 2025 | americanbankingnews.comPassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program UpdateJune 23, 2025 | globenewswire.comPassage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy DevelopmentMay 17, 2025 | msn.comPassage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestreMay 13, 2025 | zonebourse.comZPASSAGE BIO, INC. : Wedbush persiste à l'achatMay 13, 2025 | zonebourse.comZPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsMay 13, 2025 | globenewswire.comInsider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of StockApril 25, 2025 | insidertrades.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 SharesApril 18, 2025 | insidertrades.comOrbiMed Advisors vend des actions de Passage Bio pour 49.704$April 18, 2025 | fr.investing.comL’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marchéApril 8, 2025 | fr.investing.comL’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$March 31, 2025 | fr.investing.comL'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$March 14, 2025 | fr.investing.comPassage Bio (PASG) Upgraded to Buy: Here's What You Should KnowMarch 7, 2025 | zacks.comPASSAGE BIO, INC. : Chardan Research reste à l'achatMarch 5, 2025 | zonebourse.comZL’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$March 5, 2025 | fr.investing.comPassage Bio price target lowered to $6 from $7 at ChardanMarch 5, 2025 | markets.businessinsider.comPassage Bio publie ses résultats du quatrième trimestre et de l'année 2024.March 4, 2025 | zonebourse.comZNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALBT, MIRA, DARE, and PASG Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.72 -0.07 (-2.33%) As of 07/3/2025 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Dare Bioscience NASDAQ:DARE$2.41 +0.01 (+0.42%) As of 07/3/2025 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.18 -0.07 (-5.24%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.15 -0.02 (-1.79%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Passage Bio NASDAQ:PASG$0.46 +0.05 (+13.46%) Closing price 07/3/2025 03:36 PM EasternExtended Trading$0.46 0.00 (-0.22%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
